Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT04827953
Other study ID # NLM-2020-01 / NUMANTIA
Secondary ID
Status Active, not recruiting
Phase Phase 1/Phase 2
First received
Last updated
Start date September 1, 2021
Est. completion date September 30, 2024

Study information

Verified date December 2023
Source Nelum Corp
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

In order to improve the survival rates and decrease progression of pancreatic advanced cancer, this study aims to evaluate the first line treatment approved for this disease (gemcitabine plus nab-paclitaxel) in combination with two experimental drugs, an inhibitor of the signaling pathway of Hedgehog and an immunotherapy drug able of blocking the CTLA-4 receptor.


Description:

Pancreatic cancer is one of the leading neoplasms in the world in terms of mortality, with very low survival rates mainly due to its rapid progression and diagnosis in advanced stages, which makes its treatment extremely difficult. Gemcitabine plus nab-paclitaxel is currently considered the first-line standard treatment for advanced pancreatic cancer due to this superiority against other treatments. In order to find an alternative to improve survival of advanced pancreatic cancer, this study aims to evaluate the efficacy with first-line treatment in combination of two experimental drugs, a Hedgehog pathway inhibitor (NLM-001) and a CTLA-4 blocker (zalifrelimab) in previously untreated patients with advanced pancreatic cancer.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 28
Est. completion date September 30, 2024
Est. primary completion date September 30, 2024
Accepts healthy volunteers No
Gender All
Age group 18 Years to 90 Years
Eligibility Inclusion Criteria: 1. Investigators must ensure that patients are able to understand the requirements of the study and provide informed consent 2. Age =18 years 3. Histological or cytological diagnosis of pancreatic adenocarcinoma 4. Stage IV disease 5. No prior treatment for advanced disease. Patients who have received chemotherapy for localize disease are eligible if at least six months have elapsed from the last chemotherapy treatment 6. Measurable disease per RECIST 1.1 as determined by the investigator 7. ECOG (Eastern Cooperative Oncology Group) PS 0-1 8. Sufficient hematopoietic, renal and liver function as defined as: - Neutrophil count = 1.5 x 10*9 / L - Platelet count = 100 x 10*9 / L - Bilirubin = 1.5 x ULN (upper limit of normal) - AST and / or ALT =2.5 x ULN or =5 for patients with liver disease - Serum creatinine = 1.5 x ULN 9. Tumor lesion amenable for safe repeated biopsy 10. Women of child-bearing age and men who wish to participate in the study must agree to use appropriate contraceptive methods from the signing of informed consent until 3 months after discontinuation of the study drug - Adequate contraception includes abstinence, oral contraceptives, transdermal patches, and injections that prolong release of a progestogen (starting at least 4 weeks prior to the administration of the investigational drug), double barrier method: condom or female condom (diaphragm or condom / vaginal) plus spermicide, intrauterine device (IUD), implant or a vaginal ring (placed at least 4 weeks prior to administration of investigational drug) or male partner sterilization (vasectomy with documentation of azoospermia) before the inclusion of the woman in the trial if the male is the only sex partner of the woman Investigators must ensure that patients recruited will be able to meet all study requirements, including tumor biopsy, chemotherapy and monitoring Exclusion Criteria: 1. Active or uncontrolled infection, disease or serious medical condition that may interfere with the patient's eligibility or treatment 2. History of psychiatric condition that would compromise the patient's ability to understand or comply with the requirements of the protocol, or the ability to provide informed consent 3. Concurrent antineoplastic therapy 4. Pregnant or lactating women 5. History of allergic reactions attributed to compounds of similar chemical structure or similar biological study drug composition 6. History of life-threatening serious adverse events to Gemcitabine or Nab-Paclitaxel 7. Prior chemotherapy or chemo-radiation therapy for advanced pancreatic cancer 8. Patients requiring or being treated with potent CYP3A4 inhibitors and inducers 9. Other malignancies treated within the last 5 years, except in situ cervix carcinoma or nonmelanoma skin cancer 10. History of interstitial lung disease 11. Subjects with a history or presence of a known clotting disorder or difficulty achieving haemostasis will be excluded 12. Primary or secondary immunodeficiency, including immunosuppressive disease or autoimmune disease (including autoimmune endocrinopathies). Note: Subjects with diabetes type 1, vitiligo, psoriasis, hypo-, or hyperthyroid disease not requiring immunosuppressive treatment are eligible. Subjects with Type 2 diabetes mellitus are allowed 13. Subjects with a known history of human immunodeficiency virus 1 and 2, human T lymphotropic virus 1. 14. Administration of anticancer medications or investigational drugs within the following intervals before the first administration of study drug: 1. A 1-week washout is permitted for palliative radiation to non- central nervous system (CNS) disease, with medical monitor approval. Subjects must also not have had radiation pneumonitis as a result of treatment and cannot participate in the study if they are on chronic corticosteroids for radiation pneumonitis Note: Bisphosphonates and denosumab are permitted medications 2. =7 days for prior corticosteroid treatment, with the following exceptions: - Use of an inhaled or topical corticosteroid is permitted - Corticosteroid premedication for radiographic imaging for dye allergies is permitted - Use of physiologic corticosteroid replacement therapy may be approved after consultation with the medical monitor 3. =7 days for immunosuppressive-based treatment for any reason, with the exceptions noted above for prior corticosteroid treatment 4. =21 days or 5 half-lives before first dose of study treatment for all other investigational study drugs or devices. For investigational agents with long half-lives (e.g., >5 days), enrollment before the fifth half-life requires medical monitor approval 15. Has not recovered to grade =1 from toxic effects of prior therapy and/or complications from prior surgical intervention before starting therapy Note: Subjects with grade =2 neuropathy and alopecia are an exception and may enroll 16. History or presence of an abnormal ECG that, in the investigator's opinion, is clinically meaningful 17. Concurrent participation in other investigational drug trials 18. Known central nervous system (CNS) involvement as follows: - Untreated CNS metastases. - Leptomeningeal metastases. Note: Patients may be eligible if CNS metastases have been treated and patients have neurologically returned to baseline (except for residual signs and symptoms related to the CNS treatment).

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Gemcitabine
Gemcitabine 1000 mg/m2 IV on days 1, 8 and 15 (conventional chemotherapy).
Nab paclitaxel
Nab-Paclitaxel 125 mg/m2 IV on days 1, 8 and 15 (conventional chemotherapy).
NLM-001
NLM-001 will be administered three cycles consecutively followed by two rest cycles.
Zalifrelimab
Zalifrelimab administration each 6 weeks.

Locations

Country Name City State
Spain Hospital Universitari Vall d'Hebron Barcelona Cataluña
Spain Hospital Universitario Virgen De La Victoria Málaga Andalucía
Spain Hospital Universitario Donostia San Sebastián País Vasco
Spain Hospital Universitario Marqués del Valdecilla Santander
Spain Hospital Clínico Universitario de Santiago Santiago De Compostela A Coruña
Spain Hospital Universitario Miguel Servet Zaragoza Aragón

Sponsors (3)

Lead Sponsor Collaborator
Nelum Corp Agenus Inc., Apices Soluciones S.L.

Country where clinical trial is conducted

Spain, 

Outcome

Type Measure Description Time frame Safety issue
Primary Treatment efficacy according to response Objective Response Rate (ORR): Complete Response (CR) + Partial Response (PR) according to RECIST 1.1 criteria 17 months
Secondary Frequency of occurrence of adverse events Frequency of occurrence of adverse events according to NCI-CTCAE v5.0 criteria 8 months
Secondary Treatment efficacy according to disease control rate Disease Control Rate (DCR): Complete Response (CR) + Partial Response (PR) + Stable Disease (SD) evaluated by RECIST 1.1 criteria 8 months
Secondary Treatment efficacy according to progression free survival (PFS) Time in months from the patient's study enrolment until patient progression according to RECIST 1.1 criteria or death. 8 months
Secondary Treatment efficacy according to Duration of Response (DoR) Time between the date of first confirmed response to the date of the first documented tumor progression (per RECIST 1.1), or death due to any cause, whichever occurs first 8 months
Secondary Treatment efficacy according to Overall Survival (OS) Time in months since the patient's study enrolment until death. 8 months
Secondary CA 19.9 Decrease in CA 19.9 levels > 50% 8 months
Secondary Gli mRNA and SMA + CAF expression and ORR Correlation between change in Gli mRNA and SMA + CAF expression and Objective Response Rate (ORR). 1 month
Secondary Gli mRNA and SMA + CAF expression and PFS Correlation between change in Gli mRNA and SMA + CAF expression and Progression Free Survival (PFS). 1 month
Secondary Collagen structure and ORR Correlation between change in Collagen structure and Objective Response Rate (ORR) 1 month
Secondary Collagen structure and PFS Correlation between change in Collagen structure and Progression Free Survival (PFS). 1 month
Secondary Lymphocyte infiltration and ORR Correlation between change in lymphocyte infiltration and Objective Response Rate (ORR). 1 month
Secondary Lymphocyte infiltration and PFS Correlation between change in lymphocyte infiltration and Progression Free Survival (PFS). 1 month
See also
  Status Clinical Trial Phase
Recruiting NCT05209074 - Ivosidenib + mFOLFIRINOX in Patients With Resectable Pancreatic Adenocarcinoma Phase 1
Recruiting NCT04927780 - Perioperative or Adjuvant mFOLFIRINOX for Resectable Pancreatic Cancer Phase 3
Recruiting NCT04969731 - Safety and Efficacy of Immuncell-LC With Gemcitabine in Resectable Pancreatic Cancer Phase 3
Recruiting NCT05048524 - Peri-operative SLOG for Localized Pancreatic Cancer Phase 2
Terminated NCT04042480 - A Study of SGN-CD228A in Advanced Solid Tumors Phase 1
Completed NCT03257150 - A Study of the Use of Irreversible Electroporation in Pancreatic Ductal Cancer N/A
Terminated NCT04400903 - Monitoring Heart Rate Variability for the Early Detection of Pancreatic Cancer
Active, not recruiting NCT05462717 - Dose Escalation and Dose Expansion Study of RMC-6291 Monotherapy in Subjects With Advanced KRASG12C Mutant Solid Tumors Phase 1
Active, not recruiting NCT03267316 - A First-in-Human Study of CAN04 in Patients With Solid Malignant Tumors Phase 1/Phase 2
Recruiting NCT04970056 - Pancreatic Cancer Early Detection Consortium
Terminated NCT04046887 - Study of Lonsurf in Combination With Gemcitabine and Nab-Paclitaxel in Patients With Advanced (PDAC) Phase 1
Recruiting NCT05964621 - Venous Thromboembolism in Primary Pancreatic Tumour Resection
Recruiting NCT04291651 - UCSF PANC Cyst Registry
Recruiting NCT05977322 - A Phase I Study of [177Lu]Lu-FF58 in Patients With Advanced Solid Tumors. Phase 1
Recruiting NCT05692596 - The Pancreas Interception Center (PIC) for Early Detection, Prevention, and Novel Therapeutics
Active, not recruiting NCT04853017 - A Study of ELI-002 in Subjects With KRAS Mutated Pancreatic Ductal Adenocarcinoma (PDAC) and Other Solid Tumors Phase 1
Active, not recruiting NCT04862260 - Cholesterol Disruption in Combination With the Standard of Care in Patients With Advanced Pancreatic Adenocarcinoma Early Phase 1
Completed NCT03770117 - Study of the Effect of Prehabilitation on Markers of Sarcopenia in Patients Undergoing Pancreatoduodenectomy for Malignant Disease
Completed NCT02259114 - A Dose-Finding Study of Birabresib (MK-8628), a Small Molecule Inhibitor of the Bromodomain and Extra-Terminal (BET) Proteins, in Adults With Selected Advanced Solid Tumors (MK-8628-003) Phase 1
Recruiting NCT04146298 - Mutant KRAS G12V-specific TCR Transduced T Cell Therapy for Advanced Pancreatic Cancer Phase 1/Phase 2